Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Healthcare Company (ACHC) Gains from Sales and Divestitures (2016 - 2025)

Historic Gains from Sales and Divestitures for Acadia Healthcare Company (ACHC) over the last 14 years, with Q3 2025 value amounting to $427070.0.

  • Acadia Healthcare Company's Gains from Sales and Divestitures rose 2477.98% to $427070.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $427070.0, marking a year-over-year increase of 2477.98%. This contributed to the annual value of $365871.0 for FY2024, which is 7401.84% down from last year.
  • Latest data reveals that Acadia Healthcare Company reported Gains from Sales and Divestitures of $427070.0 as of Q3 2025, which was up 2477.98% from $374741.0 recorded in Q2 2025.
  • Over the past 5 years, Acadia Healthcare Company's Gains from Sales and Divestitures peaked at $1.4 million during Q1 2023, and registered a low of $192282.0 during Q1 2024.
  • Its 5-year average for Gains from Sales and Divestitures is $591945.5, with a median of $374741.0 in 2025.
  • Its Gains from Sales and Divestitures has fluctuated over the past 5 years, first soared by 17160.38% in 2023, then crashed by 8634.55% in 2024.
  • Quarter analysis of 5 years shows Acadia Healthcare Company's Gains from Sales and Divestitures stood at $366048.0 in 2021, then soared by 41.64% to $518474.0 in 2022, then surged by 171.6% to $1.4 million in 2023, then tumbled by 74.02% to $365871.0 in 2024, then rose by 16.73% to $427070.0 in 2025.
  • Its Gains from Sales and Divestitures was $427070.0 in Q3 2025, compared to $374741.0 in Q2 2025 and $237478.0 in Q1 2025.